The verified directory of US psychedelic therapy providers.
Every clinic on LicensedPsychedelics is checked against its issuing license body before it appears here - FDA Spravato REMS, Oregon Psilocybin Services, Colorado DORA, state medical boards, ASKP3. No pay-to-play rankings. No fake reviews.
Featured clinics
Hand-picked practices with deep verification
Featured listings have passed credential review plus a team-level check on safety protocols, intake process and patient-facing pricing transparency.
By modality
Know the treatment, then the provider
Each modality has its own regulatory body, insurance mechanics, clinical evidence and price range. Start with the one you are actually looking for.
Spravato (esketamine)
FDA-approved esketamine. REMS-certified sites only. Often covered by insurance for treatment-resistant depression.
Ketamine IV infusion
Infusion protocols run by board-certified prescribers. The best-studied route for off-label ketamine in depression.
Psilocybin (Oregon licensed)
Oregon adult-use psilocybin at a licensed OHA service center. 21+, no prescription required.
Psilocybin (Colorado licensed)
Colorado natural medicine healing centers. Licensed since 2025 under DORA.
How we verify
Credentials checked against the body that issued them
There are plenty of slick psychedelic directories. Most of them rely on self-reported listings. We do not. Every license number on this site is matched against the public record at the issuing authority before the listing goes live, and then re-checked on a rolling 30-day cycle.
See the full methodology- 01
FDA REMS registry
Spravato sites are cross-checked against the FDA-maintained Risk Evaluation and Mitigation Strategy directory daily.
- 02
State licensure
Oregon Psilocybin Services (OHA) and Colorado DORA natural medicine licenses pulled weekly; state medical boards checked on a 30-day cycle.
- 03
ASKP3 + NPI
Practitioners cross-referenced against the American Society of Ketamine Physicians and the CMS National Provider Identifier registry.
- 04
Manual review
Featured listings get an additional manual pass: protocol review, pricing transparency, intake process, safety posture.
By state
Legal status varies significantly
From licensed psilocybin programs in Oregon and Colorado to ketamine-only access in the Southeast - start with what is actually available where you live.
First state with a regulated adult-use psilocybin services program (Measure 109, operational since January 2023). Any adult 21+ can book a licensed session; no medical diagnosis or referral required. Over 30 licensed service centers operate under the Oregon Psilocybin Services (OPS) division of OHA.
Voters passed Proposition 122 in 2022 creating the Natural Medicine Health Act. Regulated healing centers began operating in 2025 under the Colorado Department of Regulatory Agencies (DORA). Program covers psilocybin initially; DMT, ibogaine and mescaline are scheduled to be added in later phases.
Oakland, Santa Cruz, Berkeley, San Francisco and Arcata have decriminalized possession of plant-based psychedelics. Statewide SB 1012 (Therapeutic Psilocybin Act) is in legislative review. No licensed psilocybin program yet; ketamine and Spravato are widely available in all major metros.
Assembly Bill A114 would authorize a regulated psilocybin program modelled on Oregon. Senate companion in committee. In the meantime, NYC is the densest US market for IV ketamine and Spravato, with multiple concierge and insurance-accepting practices.
HB 1802 (2021) funded a psilocybin research study at Baylor College of Medicine; no treatment program yet. Ketamine and Spravato are widely available. Texas has the second-largest number of ketamine clinics after California.
No state psychedelic legislation. Large snowbird ketamine market around Bonita Springs, Naples and Palm Beach. Spravato coverage via Florida BCBS, Aetna and several Medicare Advantage plans.
Somerville, Cambridge, Northampton and Salem have decriminalized plant-based psychedelics. Question 4 (statewide psilocybin) failed in 2024 but is expected to return on a future ballot. Strong Spravato coverage via Mass General Brigham network and Tufts Health Plan.
Seattle and Port Townsend decriminalized in 2021. SB 5263 (2024) established a state psilocybin task force that reported recommendations in early 2026. Ketamine is widely available; Spravato coverage via Regence BCBS and Premera.
CURE Act (SB 2308) would create a regulated psilocybin services program. Still in committee. Chicago is a solid ketamine/Spravato market with BCBS IL covering Spravato for MDD and MDSI.
SB 1570 (2023) funded $5M in psilocybin research grants. Policy momentum building. Ketamine scene centered on Scottsdale and Phoenix, catering to wellness and recovery markets.
No psilocybin legislation on the horizon. Ketamine and Spravato widely available in Atlanta metro. Emory Healthcare runs the largest academic psychedelic treatment program in the Southeast.
HF 1884 created a Psychedelic Medicine Task Force that reported to the legislature in 2024. Bill to establish a regulated program expected to be reintroduced in 2026 session. Mayo Clinic and University of Minnesota are active research sites.
For clinics
If your practice is listed, claim it
A free verified listing stays free. Claiming lets you update pricing, hours, the intake process and insurance; respond to patient questions; and see what searches are driving traffic to your listing. Featured placements and lead-gen packages are optional and priced transparently.
Verified listing + license badge
Forever free
Featured placement + enhanced profile
Opt-in
Lead-gen + form routing + call tracking
Pay-per-result
Patient resources
Guides without the marketing spin
news
Trump signs executive order fast-tracking psychedelic therapy: what it actually does
On April 18, 2026, President Trump signed an executive order directing the FDA to issue Priority Vouchers for psychedelic drugs, opening Right to Try access to ibogaine, and routing $50M through ARPA-H. Podcast host Joe Rogan, RFK Jr., Dr. Oz and Navy SEAL Marcus Luttrell attended. Here is a plain-English breakdown of every moving part.
legal
Is ibogaine legal in the United States? (Updated for the 2026 executive order)
Ibogaine is Schedule I in the US, but the April 2026 executive order opens a Right to Try pathway for eligible patients. Here is what is legal today, what changes in 60 days, and where US patients actually access treatment right now.
legal
The Right to Try Act and psychedelics: how patient access actually works in 2026
The 2026 executive order directs FDA and DEA to create a Right to Try pathway for investigational psychedelics. Here is how the law works, who qualifies, what drug sponsors have to do, and the realistic timeline for patients.